Solana whales make moves ahead of October spot SOL ETF approvals

來源 Cryptopolitan

Solana (SOL) is gaining traction on whale activity, as large-scale entities moved to load up on tokens. The asset may extend its bull market ahead of the October 10 ETF approval deadline. 

Solana (SOL) is gaining traction as more whale wallets are accumulating tokens. The final stretch until the spot ETF approval deadline is seen as an accumulation period, potentially extending the SOL bull market. 

On October 10, the US Securities and Exchange Commission will have to issue a statement on the launch of a new spot ETF. As Cryptopolitan reported earlier, the ETF has a 95% chance of approval. 

As a result, whales rushed in to move SOL out of Coinbase Prime. The Coinbase Prime wallet has been sending out thousands of SOL, with several large-scale transactions going to four newly created wallets, possibly belonging to one entity

Whales rush to Solana as spot ETF approval approaches
An entity made multiple SOL transactions, accumulating assets ahead of an expected ETF launch. | Source: Solscan

Competition for SOL may accelerate, as the tokens are in demand for treasuries, as well as eventual ETF reserves. SOL has ended the most active period of unlocks, and while there are still potential sellers, the token may see accumulation similar to ETH. 

Galaxy Digital also put $40M SOL in its custody, after a series of withdrawals from Coinbase and Binance. 

Solana treasuries are also at the beginning of their journey, with just six entities announced. Those buyers hold 4.4M SOL, and are currently outcompeted by older whales. DeFi Dev Corp and Exodus Movement added to their treasuries in the past week. 

SOL among daily liquidation leaders

Following an active period for the Solana ecosystem, SOL broke to a higher price range. The asset is back above $220, causing market-wide short liquidations. The asset peaked at $222.10, attacking the accumulated short positions. 

As of September 10, Coinglass data showed $7.1M in SOL liquidations, as the token became one of the day’s leading gainers. 

Other estimates saw over $17M in liquidated SOL positions, as on-chain liquidations once again surpassed centralized activity. The short liquidations followed a SOL breakout above $220 for the first time in eight months. 

SOL sets expectations for a higher price range

SOL is currently trading with a “greed” sentiment based on its specific fear and greed index. Short-term expectations see SOL entering price discovery at over $250 and potentially rising to four-digit assets. 

SOL is being compared to ETH, which started its bull rally from $217 and set records close to $4,900. While this took years, SOL hopes on adoption and on-chain activity to boost the network. Mainstream acceptance through spot ETFs and treasuries may further boost the price expansion. 

SOL is currently in a range between $216 and $225 based on accumulated liquidity on long and short positions.

Open interest remains near its all-time high at $7.75B. Short traders are becoming bolder, with nearly 40% of all SOL positions attempting to short the asset. This may lead to further liquidations if SOL keeps up its rally.

Join Bybit now and claim a $50 bonus in minutes

免責聲明:僅供參考。 過去的表現並不預示未來的結果。
placeholder
黃金七連漲終結!是上車機會還是牛市拐點?​2025年9月4日,瘋狂上漲的黃金終於「喘了口氣」——國際金價在連續七日創新高後回檔0.38%,收報3545.78美元/盎司。很多投資人一邊糾結是不是該獲利了結,一邊又怕錯過後續行情。
作者  投資-槓把子
9 月 05 日 週五
​2025年9月4日,瘋狂上漲的黃金終於「喘了口氣」——國際金價在連續七日創新高後回檔0.38%,收報3545.78美元/盎司。很多投資人一邊糾結是不是該獲利了結,一邊又怕錯過後續行情。
placeholder
外資連5日賣超,台船(2208)股價攀升的背後,是大筆軍工訂單正在趕來台船(2208)股價近期再度上揚,從8月28日低點18.15元,一路攀升至9月8日高點27.1元,上漲幅度高達49.3%。雖然今日(9日)小幅回落,目前報價為25.65元,但受惠於優異的8月業績表現,以及潛在大單即將進帳的利多消息,台船已遭外資連續5日賣超,顯示市場對其前景的強烈期待。
作者  財富進化論
昨日 03: 12
台船(2208)股價近期再度上揚,從8月28日低點18.15元,一路攀升至9月8日高點27.1元,上漲幅度高達49.3%。雖然今日(9日)小幅回落,目前報價為25.65元,但受惠於優異的8月業績表現,以及潛在大單即將進帳的利多消息,台船已遭外資連續5日賣超,顯示市場對其前景的強烈期待。
placeholder
康霈*減重藥遭FDA一拳重擊!股價跳空跌停 賣單高掛上萬張 散戶集體出逃?​投資慧眼Insights-因減肥藥進展受阻,生技股康霈*(6919)今(10)日早盤開盤即跌停鎖死在229.5元,暴跌10%。
作者  投資指南針
12 小時前
​投資慧眼Insights-因減肥藥進展受阻,生技股康霈*(6919)今(10)日早盤開盤即跌停鎖死在229.5元,暴跌10%。
placeholder
康霈*澄清來得太遲!1.5萬張賣單說明一切:一場由減肥藥夢碎引發的踩踏遠未結束生物科技股康霈*(6919)昨日法說會拋出減肥新藥臨床試驗延期半年的消息,儘管公司火速發布聲明強調是"主動選擇推遲",卻難以掩蓋股價一日跌停鎖死、1.5萬張賣單排隊的殘酷現實。這場被市場解讀為"欲蓋彌彰"的澄清,反而揭露了生物科技股過度投機的問題本質。
作者  投資-槓把子
8 小時前
生物科技股康霈*(6919)昨日法說會拋出減肥新藥臨床試驗延期半年的消息,儘管公司火速發布聲明強調是"主動選擇推遲",卻難以掩蓋股價一日跌停鎖死、1.5萬張賣單排隊的殘酷現實。這場被市場解讀為"欲蓋彌彰"的澄清,反而揭露了生物科技股過度投機的問題本質。
placeholder
甲骨文股價狂飆近三成!雲端訂單衝4550億美元 CEO親曝:這三家下了大訂單​投資慧眼Insights-甲骨文(ORCL.US)最新一季度業績大爆發,盤後股價一度狂飆接進30%。
作者  投資指南針
7 小時前
​投資慧眼Insights-甲骨文(ORCL.US)最新一季度業績大爆發,盤後股價一度狂飆接進30%。
goTop
quote